Daily Chart: Inventiva vs. Intercept in NASH

Data from the Phase IIb NATIVE trial show lanifibranor produced response rates in NASH patients that were superior to Phase III data for the indication’s most advanced candidate, obeticholic acid from Intercept, which is under FDA review with a decision expected after June 26 (see “Inventiva Resuscitates Hopes for PPAR in NASH”). ...